Moderna, Inc. (MRNA)

From the record

Moderna, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Moderna, Inc.'s 6 filed years say what it did: revenue went from $60 million in fiscal 2019 to $1.9 billion in fiscal 2025, up 78.4% a year; it rose in 2 of 5 years; the deepest fall was 90% from fiscal 2022 to fiscal 2025; net income was positive in 2 of 7 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Moderna, Inc. lost about 33 cents for every dollar of shareholders' money, and gross profitability: its products earned about 9 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 30 cents per dollar of assets, and net share issuance: its share count grew 1.3% over the year (the filed statements).

From the record

Moderna, Inc.'s standing among 102 graded names in its industry family: revenue of $1.9 billion in fiscal 2025 ranks in the top 6% by size; a net margin of -145.2% ranks in the top 41%; revenue growth of -53.4% a year over the last 3 filed years ranks in the bottom 8% (its annual reports).

From the record

Moderna, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Bancel, Stephane (Chief Executive Officer, as filed), filing under that title since 2018-12-07, 7.9 years (top 20% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 6.5 years (top 28%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 35%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Moderna, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $2.6 billion against debt of $590 million leaves 16.3% of its assets as net cash, bottom 27% of its family; cash from operations less capital spending is -106.2% of revenue (top 40%); a gross margin of 55.3% (bottom 35%); research spending of 161.1% of revenue (top 49%) (its annual report).

From the record

Moderna, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -53.4% a year over the last three filed years against 78.4% over all 6, slowing (bottom 3% of its family); the newest year grew -39.9% (bottom 17%); research spending grew -1.7% a year (bottom 42%); capital spending grew -21.7% a year (top 43%) (its annual reports). Moderna, Inc. reported 6 product lines in fiscal 2025: COVID19 at $1.8 billion (93%), Stand Ready Manufacturing Revenue at $80 million (4%), Grant at $22 million (1%), and 3 more; 0 of 5 grew against the year before (its annual report).

From the record

Moderna, Inc.'s newest year against its own record: revenue of $1.9 billion in fiscal 2025 came in 46.5% above the $1.3 billion its prior three years' pace pointed to (top 30% of its family); net income of $2.8 billion against a prior three-year average of $29 million (bottom 2%); a net margin of a loss larger than its revenue against -45.2% before (bottom 24%) (its annual reports).